Treatment of bicalutamide-induced breast events

@article{Sieber2007TreatmentOB,
  title={Treatment of bicalutamide-induced breast events},
  author={Paul R. Sieber},
  journal={Expert Review of Anticancer Therapy},
  year={2007},
  volume={7},
  pages={1773 - 1779}
}
  • P. Sieber
  • Published 2007
  • Medicine
  • Expert Review of Anticancer Therapy
Bicalutamide is a competitive nonsteroidal androgen receptor antagonist. In the European Union and a number of other countries, bicalutamide 150 mg per day is approved as an adjuvant to primary treatments (radical prostatectomy or radiotherapy) or as monotherapy as an alternative to surgical or medical castration in men with locally advanced, nonmetastatic prostate cancer. The ongoing bicalutamide Early Prostate Cancer (EPC) program has shown that breast events, defined as gynecomastia, breast… Expand
Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysis.
TLDR
A meta-analysis suggests using prophylactic tamoxifen 20 mg daily as the first-line preventive measure and radiotherapy as thefirst-line treatment option for bicalutamide-induced gynecomastia. Expand
Aromatase Inhibitors Beyond Breast Cancer: Endometrium Versus Breast Puzzle and Other Issues
TLDR
The expansion of the attempts to use aromatase inhibitors beyond the mammary cancer field suggests that these drugs can be beneficial in some other cancers as well as noncancerous conditions, and makes another incentive to study the mechanisms of resistance to aromat enzyme inhibitors. Expand
Findings of Gynecomastia That Developed in Follow-up Secondary to Bicalutamide Treatment on Bone Scan
TLDR
Blood pool images showed bilateral hyperemia in the breast regions which was not present on the previous scan one year ago and it was learned that the patient was given Bicalutamide therapy after the first bone scan. Expand
Quality of life issues in men undergoing androgen deprivation therapy: a review.
TLDR
A review of the adverse effects on quality of life (QoL) issues in the following areas: body feminisation, sexual changes, relationship changes, cognitive and affective symptoms, fatigue, sleep disturbance, depression and physical effects. Expand
Androgen Deprivation Therapy for Prostate Cancer : Recommendations to Improve Patient and Partner Quality of Lifejsm
Introduction. Because of improved prostate cancer detection, more patients begin androgen deprivation therapy (ADT) earlier and remain on it longer than before. Patients now may be androgen deprivedExpand
Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only
TLDR
A 60-year-old patient, initially presenting with a PSA elevation of 19.2 ng/mL in 1996, is reported, who underwent an open radical prostatectomy and adenocarcinoma of the prostate, classified as pT3a, pR1, pV0, and pL1 in 2001. Expand
Management of the side effects of androgen deprivation therapy in men with prostate cancer
TLDR
Despite the long history of androgen deprivation therapy use in prostate cancer, ongoing work continues to identify and define the adverse events better and for each complication, recent efforts continue to characterize the problem and its rational management. Expand
Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
TLDR
Patients treated with ADT are at increased risk of several adverse events and should be routinely monitored for the development of potentially significant morbidity/mortality. Expand
Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life.
TLDR
It is hoped that this plan will serve as a guide for optimizing how ADT is carried out and improve the lives of androgen-deprived men and their intimate partners. Expand
Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.
TLDR
SNARE-1 inhibits AR function by a mechanism that is distinct from clinically available antiandrogens, such that it might inform novel methods to block AR function in androgen-independent prostate cancer. Expand
...
1
2
...

References

SHOWING 1-10 OF 53 REFERENCES
Tamoxifen for flutamide/finasteride-induced gynecomastia.
TLDR
Preliminary results suggest that low-dose tamoxifen is useful in treating painful gynecomastia for those patients on flutamide/finasteride combination therapy for advanced prostate carcinoma. Expand
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
PURPOSE Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in whichExpand
Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.
TLDR
Therapeutic radiotherapy, using two fractions of 6 Gy external-beam radiation to the male breast, improves the intensity of bicalutamide-induced gynaecomastia and/or breast pain in approximately one-third of patients. Expand
Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
  • D. Gillatt
  • Medicine
  • Journal of Cancer Research and Clinical Oncology
  • 2006
TLDR
The available evidence indicates that the different antiandrogens should not be regarded as equivalents in clinical practice and so the choice of treatment for patients with prostate cancer should be made on an individual basis. Expand
The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer
TLDR
In patients with locally advanced disease, bicalutamide 150 mg adjuvant to radiotherapy demonstrates significant clinical benefits in terms of overall survival, PFS and PSA–PFS compared with radiotherapy alone and is consistent with the overall results from the EPC program. Expand
Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
TLDR
It is suggested that prophylactic tamoxifen 20 mg/d is an effective dose for reduction of bicalutamide-induced breast events and does not appear to affect disease control based on PSA suppression. Expand
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
TLDR
Anastrozole did not significantly reduce the incidence of bicalutamide-induced gynecomastia and breast pain and tamoxifen was effective, without increasing adverse events, at least in the short-term follow-up, which supports the need for a larger study to determine any effect on mortality. Expand
Treatment of Locally Advanced Prostate Cancer – A New Role for Antiandrogen Monotherapy?
TLDR
In the setting of previously untreated locally advanced disease, pooled mature data from two major studies indicate no significant difference in survival outcome between bicalutamide (‘Casodex’) 150 mg and castration. Expand
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole
TLDR
Tamoxifen, but not anastrozole, significantly reduced the incidence of gynecomastia/breast pain when used prophylactically and therapeutically and any impact on cancer control is still to be investigated. Expand
Tamoxifen as treatment for gynecomastia and mastodynia resulting from hormonal deprivation.
The standard care for patients with metastatic disease or inoperable prostate cancer is orchiectomy or the administration of luteinizing hormone releasing hormone agonists with or without anExpand
...
1
2
3
4
5
...